SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Manuela Rasi, Patrizia Künzler-Heule, Patrick Schmid, David Semela, Philip Bruggmann, Jan Fehr, Susi Saxer, Dunja Nicca, “Fighting an uphill battle”: experience with the HCV triple therapy: a qualitative thematic analysis, BMC Infectious Diseases, 2014, 14, 1, 507

    CrossRef

  2. You have free access to this content2
    L. I. Backus, P. S. Belperio, T. A. Shahoumian, R. Cheung, L. A. Mole, Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort, Alimentary Pharmacology & Therapeutics, 2014, 39, 1
  3. You have free access to this content3
    Marc Bourlière, Xavier Adhoute, Astrid Wendt, Christelle Ansaldi, Valérie Oules, Paul Castellani, How to optimize current therapy of HCV genotype 1 infection with boceprevir, Liver International, 2014, 34,
  4. 4
    Louise Berry, Will Irving, Predictors of hepatitis C treatment response: what's new?, Expert Review of Anti-infective Therapy, 2014, 12, 2, 183

    CrossRef

  5. 5
    Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Hiroshi Abe, Chisa Kondo, Norio Itokawa, Ai Nakagawa, Katsuhiko Iwakiri, Chiaki Kawamoto, Yoshio Aizawa, Choitsu Sakamoto, Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C, Digestive and Liver Disease, 2014, 46, 8, 738

    CrossRef